Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 9, 2013, Pages 1515-1520

  Huang, Chung Feng ^a,c   Yeh, Ming Lun ^c   Hsieh, Meng Hsuan ^c   Hsieh, Ming Yen ^c   Lin, Zu Yau ^a,c   Chen, Shinn Cherng ^a,c   Wang, Liang Yen ^a,c   Huang, Jee Fu ^a,c,d   Juo, Suh Hang Hank ^b   Lin, Yi Ching ^a,c   Dai, Chia Yen ^a,c   Chuang, Wan Long ^a,c   Yu, Ming Lung ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

HCV 1; IL 28B; Re treatment

Indexed keywords

INTERFERON; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; ASIAN; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE;

HCV-1; IL 28B; RE-TREATMENT;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RECURRENCE; RETREATMENT; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84897584496     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12211     Document Type: Article

References (33)

1. Yang JF, Lin CI, Huang JF etal. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J. Med. Sci. 2010; 26: 461-469.
2. Yu ML, Lin SM, Chuang WL etal. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 2006; 11: 985-994.
3. Huang JF, Yu ML, Lee CM etal. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1, 386-patient study from Taiwan. Aliment. Pharmacol. Ther. 2007; 25: 1029-1037.
4. Yu ML, Dai CY, Huang JF etal. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
5. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009; 24: 336-345.
6. Di Bisceglie AM, Shiffman ML, Everson GT etal. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 2008; 359: 2429-2441.
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
8. Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J. Hepatol. 2005; 43: 243-249.
9. Oze T, Hiramatsu N, Yakushijin T etal. Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. J. Gastroenterol. 2011; 46: 1031-1037.
10. Jacobson IM, Gonzalez SA, Ahmed F etal. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol. 2005; 100: 2453-2462.
11. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment. Pharmacol. Ther. 2010; 32: 969-983.
12. Huang CF, Huang JF, Yang JF etal. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J. Hepatol. 2012; 56: 34-40.
13. Huang CF, Yeh ML, Huang JF etal. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res. 2012; 93: 239-244.
14. Liu CH, Liang CC, Liu CJ etal. Interleukin 28B genetic polymorphisms and viral factors help identify hepatitis C virus genotype 1 patients who benefit from 24 week of peginterferon plus ribavirin therapy. Antivir. Ther. 2012; 17: 477-484.
15. Jensen DM, Pol S. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012; 32 (Suppl. 1): 74-78.
16. Omata M, Kanda T, Yu M-L etal. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol. Int. 2012; 6: 409-435.
17. Yu ML, Dai CY, Huang JF etal. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.
18. Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML. Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011; 53: 367-368; author reply 8.
19. Yu ML, Huang CF, Huang JF etal. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
20. Vermehren J, Yu ML, Monto A etal. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J. Clin. Virol. 2011; 52: 133-137.
21. Okamoto H, Tokita H, Sakamoto M etal. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J. Gen. Virol. 1993; 74 (Pt 11): 2385-2390.
22. Martinez SM, Fernandez-Varo G, Gonzalez P etal. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2011; 33: 138-148.
23. Yoshida H, Arakawa Y, Sata M etal. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-491.
24. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin. Gastroenterol. Hepatol. 2010; 8: 280-288, 8 e1.
25. Jensen DM, Marcellin P, Freilich B etal. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann. Intern. Med. 2009; 150: 528-540.
26. Poynard T, Colombo M, Bruix J etal. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28 e2.
27. Bacon BR, Shiffman ML, Mendes F etal. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49: 1838-1846.
28. Oze T, Hiramatsu N, Mit E etal. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatol. Res. 2013; 43: 35-43.
29. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
30. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
31. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
32. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann. Intern. Med. 2012; 156: 279-290.
33. Liu CH, Liu CJ, Lin CL etal. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008; 47: 1260-1269.